Bradykinin and high glucose promote renal tubular inflammation
Open Access
- 18 November 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 25 (3) , 698-710
Abstract
Background. The role of the kallikrein–kinin system in diabetic nephropathy remains controversial. Methods and Results. High-glucose (HG) super-induced interleukin (IL)-6, CCL-2, transforming growth factor (TGF)-β, vascular endothelial growth factor (VEGF) and B2K receptor (B2KR) mRNA in cultured proximal tubular epithelial cells (PTEC), whereas bradykinin (BK) upregulated IL-6, CCL-2 and TGF-β mRNA. HG activated mitogen-activated protein kinase (MAPK) p42/p44 and protein kinase C (PKC) signals, whereas BK only activated MAPK. Tubular expression of these mediators and tissue kallikrein 1 (KLK1) was confirmed in human diabetic kidney biopsies. Inhibition of MAPK p42/p44 by PD98059 partially reduced HG and BK induction of IL-6, CCL-2 and TGF-β, whereas inhibition of PKC by staurosporine partially reduced HG- but not BK-induced overexpression of these cytokines and that of VEGF. Staurosporine and PD98059 synergistically reduced the effect of HG on IL-6, CCL-2 and TGF-β expression. The B2KR blocker, icatibant, downregulated BK- and HG-induced MAPK p42/p44 but not HG-induced PKC activation and partially reduced both HG- and BK-induced IL-6, CCL-2 and TGF-β secretion. HG stimulated expression of KLK1 and low-molecular-weight kininogen (LMWK) and its downstream effects were attenuated by aprotinin (tissue kallikrein inhibitor). The peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, rosiglitazone, attenuated HG-induced PKC but not HG- or BK- induced MAPK p42/44 activation and reduced HG-stimulated VEGF, along with IL-6, CCL-2 and TGF-β secretion. Rosiglitazone plus icatibant further reduced these effects of HG. Conclusions. In conclusion, HG stimulates tubular proinflammatory, profibrotic and angiogenic signals, which is partly mediated through BK via MAPK signalling and partly through PKC independent of BK. The potential therapeutic role of complementary B2KR blockade and PPAR-γ activation deserves clinical investigation.Keywords
This publication has 40 references indexed in Scilit:
- Role of PPARγ in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potentialClinical Science, 2008
- The Death Ligand TRAIL in Diabetic NephropathyJournal of the American Society of Nephrology, 2008
- Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathyAmerican Journal of Physiology-Renal Physiology, 2007
- Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the wayDiabetologia, 2006
- High glucose increases B1-kinin receptor expression and signaling in endothelial cellsBiochemical and Biophysical Research Communications, 2006
- Activation of Tubular Epithelial Cells in Diabetic Nephropathy and the Role of the Peroxisome Proliferator–Activated Receptor-γ AgonistJournal of the American Society of Nephrology, 2006
- IL-10, IL-6, and TNF-α: Central factors in the altered cytokine network of uremia—The good, the bad, and the uglyKidney International, 2005
- Mechanisms through which bradykinin promotes glomerular injury in diabetesAmerican Journal of Physiology-Renal Physiology, 2005
- Inhibition of IGF-I–induced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykininKidney International, 2002
- Global and societal implications of the diabetes epidemicNature, 2001